51. Diagnostic Performance of Four Fecal Immunochemical Tests for Detecting Advanced Colorectal Neoplasia: Preliminary Results
- Author
-
Seth D. Crockett, Jeanette M. Daly, Richard M. Hoffman, AD Levin, Jeffrey D. Dawson, Marc J. Zuckerman, Y Xu, Daniel S. Reuland, Navkiran K. Shokar, and Barcey T. Levy
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,Epidemiology ,Colorectal cancer ,business.industry ,Incidence (epidemiology) ,Stool testing ,Colonoscopy ,Gold standard (test) ,Stool specimen ,medicine.disease ,law.invention ,Oncology ,Randomized controlled trial ,law ,Internal medicine ,medicine ,business ,Feces - Abstract
Screening programs based on fecal blood testing have been shown in randomized controlled trials to reduce colorectal cancer incidence and mortality. Professional organizations highly recommend screening average-risk patients with fecal immunochemical testing (FIT). Many patients find these stool tests more acceptable than colonoscopy and stool testing may be the preferred option for areas with limited endoscopic resources. However, the diagnostic performance of FIT testing, particularly for CLIA-waived point-of-care (POC) tests, has not been well studied. Purpose: We are comparing the diagnostic accuracy of 4 FIT tests, one automated (AUTO) and 3 POC, for detecting advanced neoplasia (advanced adenomas and carcinomas) using colonoscopy as a gold standard. Methods. We are enrolling subjects ages 50 to 85 at 3 academic medical centers in Iowa, Texas, and North Carolina who were scheduled for a screening or surveillance colonoscopy. Each subject completed 4 different FIT tests on a single stool specimen. Based on colonoscopy results, we calculated sensitivity, specificity, and predictive values. We used PROC GLIMMIX models in SAS to compare sensitivity and specificity across the different tests, accounting for the within-patient correlation. Results: We currently have 641 subjects who completed FIT and colonoscopy. Mean age is 61.2 (±7.5) years, 63% women, 63% non-Hispanic white, and 31% Hispanic. We found advanced neoplasia, including 5 carcinomas, in 68 subjects. The sensitivities for detecting these neoplasia were 3%, 22%, 28%, and 16% (AUTO), respectively. Corresponding positive predictive values were 18%, 21%, 33%, and 24% (AUTO). Specificities were 97%, 89%, 90%, and 94% (AUTO), respectively, and corresponding negative predictive values were 89%, 91%, 92%, and 90% (AUTO). We found statistically significant differences in sensitivity (P < 0.01) and specificity (P < 0.01) across tests. Conclusions: Early data suggest that FIT products may vary in their sensitivity and specificity for detecting advanced colorectal neoplasia. This variability could have important impacts on the effectiveness of efforts to limit the burden of colorectal cancer by increasing population-based screening rates through fecal blood testing.
- Published
- 2019
- Full Text
- View/download PDF